Alpha Cognition (ACOG) Q4 2024 earnings summary

Executive summary

• Achieved first earnings report post-commercial launch of ZUNVEYL for mild to moderate Alzheimer's disease, marking a major milestone.

• Raised $52.8 million in Q4 2024 to fund ZUNVEYL commercial launch and Nasdaq uplisting, significantly strengthening liquidity.

• Completed initial commercial manufacturing and supply chain for ZUNVEYL on schedule and on budget, with all strengths available for pharmacy orders.

• Signed a $44 million ex-US distribution deal for ZUNVEYL with China Medical System Holdings, including royalties and a $3 million upfront payment.

• Secured a new US composition of matter patent for ZUNVEYL, extending protection through 2044 in the US and 2041 globally.

Financial highlights

• Cash and cash equivalents were $48.6 million as of December 31, 2024, up from $1.4 million at year-end 2023, driven by the capital raise.

• Q4 2024 operating loss was $2.5 million, up 5% year-over-year due to higher G&A expenses from the U.S. equity offering.

• Full year 2024 operating loss was $11.9 million, compared to $9.9 million in 2023, mainly from increased consulting and professional fees.

• Net loss for Q4 2024 was $5.7 million ($0.51/share), unchanged from Q4 2023; full year 2024 net loss was $14.6 million ($2.02/share), compared to $13.8 million ($3.84/share) in 2023.

• General and administrative expenses for full year 2024 were $7.9 million, up from $5.1 million in 2023; R&D expenses were $3.9 million, down from $4.9 million.

Outlook and guidance

• No revenue guidance for 2025; operating expenses expected to range from $38 million to $42 million for the year.

• Cash runway expected to last approximately two years at current utilization rates.

• Management anticipates cash is sufficient to reach break-even in year three of launch, assuming execution of internal revenue forecasts and expense discipline.

• Break-even timeline depends on successful sales execution and expense management; expansion into new indications or clinical programs may require additional capital.

• Focused on commercialization excellence for ZUNVEYL in the US and regulatory/product approval in Asia.